Base Year
Historical Year
Forecast Year
The global hereditary angioedema therapeutic market was estimated at USD 3.47 billion in 2023 and is predicted to grow at a CAGR of 8.90% in the forecast period of 2024-2032 to achieve USD 7.48 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Globally, the rising cases of hereditary angioedema (HAE) is a key driver of the market. The condition affects between 1-9 individuals per 100,000 population, according to the National Organization for Rare Disorders (NORD). Due to underreporting and misdiagnosis, the actual number of people with the condition is significantly higher.
The hereditary angioedema therapeutic industry can be divided based on segments like drug class, treatment type, and route of administration.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised based on drug class into:
The industry can be divided based on treatment types as:
The industry can be classified based on the route of administration:
The EMR report looks into the regional markets of hereditary angioedema therapeutic like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The hereditary angioedema therapeutic market is being driven by the increasing awareness-raising activities among the general population. The lack of awareness of hereditary angioedema therapeutic is the main reason for misdiagnosis, which in turn results in patients receiving insufficient care. Some patients with hereditary angioedema are misdiagnosed with appendicitis, gastrointestinal disorders, and other non-allergic angioedema conditions. A small number of patients misdiagnosed for the disorder provides a large pool of patients with significant medical needs. This is expected to be a key market driver for hereditary angioedema therapeutic in the coming years.
The report presents a detailed analysis of the following key players in the global hereditary angioedema therapeutic market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The global hereditary angioedema therapeutic market reached a value of USD 3.47 billion in 2023.
The market is projected to grow at a CAGR of nearly 8.90% in the forecast period of 2024-2032.
The market is estimated to reach a value of about USD 7.48 billion by 2032.
The major drivers of the industry include the rising disposable incomes, increasing population, and the rising awareness-raising activities among the general population.
The expansion of healthcare sector across emerging economies is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
The leading drug classes in the industry are C1-esterase inhibitor, bradykinin B2 receptor antagonist, and kallikrein inhibitor, among others.
The significant treatment types in the market are prophylaxis treatment and on-demand treatment.
The major routes of administration in the industry are intravenous, subcutaneous, and oral.
The leading players in the market are Shire PLC, BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, and Attune Pharmaceuticals, Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share